Amyloidosis

1. Overview

Amyloidosis is a group of rare but serious conditions caused by the extracellular deposition of misfolded protein fibrils (amyloid) in tissues and organs. These insoluble fibrils disrupt normal organ function, leading to progressive failure. [1,2]

Key Classifications

The disease is classified by the precursor protein:

1. AL Amyloidosis (Light Chain): Most common systemic form. Due to clonal plasma cell disorder producing toxic immunoglobulin light chains (kappa or lambda). Medical emergency requiring rapid intervention. [3]
2. ATTR Amyloidosis (Transthyretin):
   • Wild-type (ATTRwt): Age-related (Senile Cardiac Amyloidosis). Increasingly recognized cause of heart failure with preserved ejection fraction (HFpEF) in elderly men.
   • Hereditary (ATTRv): Genetic TTR mutation. Presents with mixed polyneuropathy and cardiomyopathy phenotype. [4]
3. AA Amyloidosis (Serum Amyloid A): Secondary to chronic inflammation (rheumatoid arthritis, inflammatory bowel disease, chronic infections like tuberculosis or bronchiectasis). Predominantly affects kidneys, liver, and spleen. [5]

Why This Matters

• Underdiagnosed: Often missed cause of heart failure and nephrotic syndrome, especially in the elderly. Prevalence of ATTRwt in HFpEF populations may be 10-15%. [6]
• Time-Critical: AL amyloidosis progresses rapidly (median survival less than 6 months untreated in advanced cardiac involvement); early chemotherapy is lifesaving.
• New Therapies: Game-changing treatments for ATTR (Tafamidis, Patisiran, Inotersen) and AL (Daratumumab-based regimens) have revolutionized outcomes. [7,8]

Epidemiology

• AL Amyloidosis: Incidence 8-12 per million per year. Median age at diagnosis 65 years. Male predominance (2:1).
• ATTRwt: Predominantly affects men > 60 years. Autopsy studies suggest 10-25% of men > 80 may have some cardiac ATTR deposition.
• AA Amyloidosis: Declining in developed countries due to better control of chronic inflammatory conditions. Prevalence 5-10% in patients with long-standing rheumatoid arthritis or familial Mediterranean fever. [9]

---

2. Molecular Pathophysiology

The Amyloid Fibril Formation Cascade

┌─────────────────────────────────────────────────────────────────────────────┐
│                       AMYLOIDOSIS PATHOPHYSIOLOGY                           │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │                 PRECURSOR PROTEIN PRODUCTION                        │   │
│   │  • AL: Clonal plasma cells → Unstable light chains (κ or λ)         │   │
│   │       - Bone marrow infiltration typically less than 10%                     │   │
│   │       - Light chains are inherently nephrotoxic and cardiotoxic     │   │
│   │  • ATTR: Hepatocytes → Transthyretin (TTR)                          │   │
│   │       - Wild-type: Normal TTR but age-related instability           │   │
│   │       - Variant: > 150 mutations (V122I, T60A most common)           │   │
│   │  • AA: Hepatocytes → Serum Amyloid A (SAA)                          │   │
│   │       - Acute phase reactant (↑100-1000x in inflammation)           │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │                    MISFOLDING & AGGREGATION                         │   │
│   │  • Native protein loses quaternary/tertiary structure               │   │
│   │  • Conformational change → Beta-pleated sheet configuration         │   │
│   │  • Nucleation: Monomers form oligomers (toxic intermediate)         │   │
│   │  • Elongation: Protofilaments assemble into mature fibrils          │   │
│   │  • Fibrils are 7.5-10 nm diameter, non-branching, rigid             │   │
│   │  • Resistant to proteolysis (cannot be cleared by normal systems)   │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │                    TISSUE DEPOSITION (Tropism)                      │   │
│   │  • Fibrils deposit in extracellular matrix                          │   │
│   │  • Organ-specific affinity patterns:                                │   │
│   │    - AL: Heart > Kidney > Liver > Nerves > Soft tissue              │   │
│   │    - ATTR: Heart > Peripheral nerves > Autonomic system             │   │
│   │    - AA: Kidney > Liver > Spleen > GI tract                         │   │
│   │  • Deposits bind Congo Red dye (diagnostic marker)                  │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │                    ORGAN DYSFUNCTION                                │   │
│   │  • Mechanical disruption of tissue architecture                     │   │
│   │  • Direct cellular toxicity:                                        │   │
│   │    - AL light chains: Proteotoxicity to cardiomyocytes              │   │
│   │    - Oligomers induce oxidative stress, ER stress, apoptosis        │   │
│   │  • Interstitial infiltration → Stiffness:                           │   │
│   │    - Restrictive cardiomyopathy (diastolic dysfunction)             │   │
│   │    - Glomerular/tubular dysfunction (nephrotic syndrome)            │   │
│   │    - Hepatosplenomegaly (space-occupying effect)                    │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

AL Amyloidosis-Specific Mechanisms

• Light Chain Structure: Misfolded immunoglobulin light chains (especially variable domain VL) from a clonal plasma cell population.
• Lambda > Kappa: Lambda (λ) chains are 2-3x more common than kappa (κ) in AL amyloidosis (opposite to normal serum ratio).
• Direct Cardiotoxicity: Pre-fibrillar light chain oligomers cause cardiomyocyte calcium dysregulation, oxidative damage, and apoptosis—distinct from mechanical fibril deposition.
• Renal Toxicity: Light chains are filtered by glomeruli, causing podocyte injury and tubular toxicity even before overt fibril deposition. [10]

ATTR Amyloidosis-Specific Mechanisms

• TTR Tetramer Dissociation: Native TTR is a homotetrameric transport protein (binds thyroxine and retinol-binding protein).
• Destabilization: Age-related or mutation-induced instability causes tetramer dissociation → monomer misfolding → aggregation.
• Cardiac Tropism: TTR fibrils preferentially deposit in myocardium and peripheral nerves.
• Carpal Tunnel Syndrome: Bilateral CTS often precedes cardiac manifestations by 5-10 years in ATTR (ligament deposition). [11]

AA Amyloidosis-Specific Mechanisms

• SAA Protein: Acute phase reactant produced during chronic inflammation (IL-6 and IL-1β driven).
• Cleavage: SAA is cleaved to 76-amino acid fragments that form AA amyloid.
• Renal Predominance: AA fibrils preferentially deposit in kidneys (glomeruli), liver (sinusoids), and spleen (white pulp). [12]

Apple-Green Birefringence: The Gold Standard

The defining histological feature of all amyloid types:

• Congo Red Staining: Amyloid fibrils bind Congo Red dye (aromatic dye with affinity for beta-pleated sheets).
• Polarized Light Microscopy: Under crossed polarizers, Congo Red-stained amyloid exhibits characteristic apple-green birefringence.
• Sensitivity/Specificity: 85-95% sensitive when adequate tissue obtained; nearly 100% specific for amyloid (though does not specify type). [13]

---

3. Clinical Features

History Taking: The Multi-System Detective Work

Red Flag Symptom Clusters (Think Amyloid if ≥2 present):

Cardiac Presentation

• Breathlessness: Progressive dyspnea on exertion (restrictive cardiomyopathy).
• Edema: Peripheral, sacral, or ascites (right heart failure predominance).
• Syncope: Pre-syncope or syncope (conduction disease, autonomic dysfunction, or arrhythmia).
• Palpitations: Atrial fibrillation (common—30-40% of AL, 60-70% of ATTR).

Renal Presentation

• Frothy Urine: Proteinuria (nephrotic syndrome).
• Edema: Anasarca (severe hypoalbuminemia).
• Fatigue: Anemia (renal + chronic disease).

Neurological Presentation

• Peripheral Neuropathy: Symmetrical stocking-glove sensory loss, painful paresthesias (small fiber neuropathy).
• Autonomic Dysfunction:
  • Orthostatic hypotension (> 20 mmHg drop on standing).
  • Erectile dysfunction, bladder dysfunction.
  • Gastroparesis, chronic diarrhea/constipation.
• Bilateral Carpal Tunnel Syndrome: Especially in men > 50 with no occupational risk (highly suggestive of ATTR). [14]

Soft Tissue/Other

• Macroglossia: Enlarged tongue with dental indentations (15% of AL; pathognomonic but insensitive).
• Periorbital Purpura: "Raccoon eyes"—spontaneous or induced by Valsalva, coughing, or endoscopy (specific for AL).
• Easy Bruising: Factor X deficiency (amyloid binds Factor X) or vascular fragility.
• Hoarseness: Laryngeal deposition.
• Shoulder Pad Sign: Bilateral shoulder soft tissue swelling (amyloid myopathy).

Gastrointestinal

• Early Satiety: Gastroparesis or hepatomegaly.
• Chronic Diarrhea: Autonomic neuropathy or direct GI infiltration.
• Malabsorption: Weight loss, steatorrhea (villous infiltration).

Physical Examination Findings

---

4. Diagnosis: A Multi-Step Algorithm

Overview of Diagnostic Strategy

┌─────────────────────────────────────────────────────────────────────────────┐
│                    DIAGNOSTIC ALGORITHM FOR AMYLOIDOSIS                     │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   CLINICAL SUSPICION (Multi-system involvement or red flags)                │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │  STEP 1: SCREEN FOR MONOCLONAL PROTEIN (Rule out AL - Emergency!)   │   │
│   │  • Serum Free Light Chains (FLC) + Kappa/Lambda ratio               │   │
│   │  • Serum Protein Electrophoresis + Immunofixation (SPEP/SIFE)       │   │
│   │  • Urine Protein Electrophoresis + Immunofixation (UPEP/UIFE)       │   │
│   │  • Bone marrow biopsy if monoclonal protein detected                │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│              ↓                                           ↓                  │
│   Abnormal FLC or M-protein              Normal FLC + No M-protein          │
│   → Suspect AL                           → ATTR or AA more likely           │
│              ↓                                           ↓                  │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │  STEP 2: CONFIRM AMYLOID DEPOSITION (Tissue Diagnosis)              │   │
│   │  First-line biopsy options:                                         │   │
│   │  • Abdominal fat pad aspirate (70-80% sensitive for AL)             │   │
│   │  • Rectal biopsy (80-85% sensitive)                                 │   │
│   │  • Bone marrow biopsy (50-60% sensitive, but often done for AL)     │   │
│   │  Second-line (if negative but high suspicion):                      │   │
│   │  • Organ biopsy (Kidney, Endomyocardial, Liver)                     │   │
│   │  Histology:                                                         │   │
│   │  • Congo Red staining → Apple-green birefringence (polarized light) │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│              ↓                                                              │
│   Congo Red POSITIVE (Amyloid confirmed)                                    │
│              ↓                                                              │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │  STEP 3: AMYLOID TYPING (MANDATORY - determines treatment)          │   │
│   │  • Immunohistochemistry (κ, λ, TTR, SAA) - Limited sensitivity      │   │
│   │  • Mass Spectrometry (Laser Microdissection + MS) - Gold standard   │   │
│   │  • Genetic testing for TTR mutations (if ATTR suspected)            │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│              ↓                                                              │
│   ┌──────────────────┬─────────────────────┬──────────────────────────┐     │
│   │ AL (Light Chain) │ ATTR (Transthyretin)│ AA (Serum Amyloid A)     │     │
│   └──────────────────┴─────────────────────┴──────────────────────────┘     │
│              ↓                      ↓                       ↓               │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │  STEP 4: ORGAN STAGING & EXTENT ASSESSMENT                          │   │
│   │  • Echocardiography / Cardiac MRI                                   │   │
│   │  • Bone scintigraphy (DPD/PYP scan) for ATTR cardiac involvement    │   │
│   │  • NT-proBNP, Troponin (cardiac biomarkers)                         │   │
│   │  • 24h urine protein, eGFR (renal assessment)                       │   │
│   │  • Nerve conduction studies (if neuropathy)                         │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

Step 1: Screen for Monoclonal Protein (AL Amyloidosis)

Goal: Identify or exclude clonal plasma cell disorder.

Serum Free Light Chains (FLC)

• Test: Nephelometric assay measuring free κ and λ light chains.
• Normal Ratio: κ/λ = 0.26-1.65.
• Abnormal: Ratio less than 0.26 (λ clonal) or > 1.65 (κ clonal) suggests plasma cell dyscrasia.
• Difference (dFLC): Absolute difference between involved and uninvolved FLC (prognostic in AL). [15]

Serum Protein Electrophoresis + Immunofixation (SPEP/SIFE)

• SPEP: May show small M-spike (often less than 1 g/dL in AL; 70% have detectable paraprotein).
• Immunofixation: More sensitive—identifies monoclonal band type (IgG, IgA, IgM, κ, λ).

Urine Protein Electrophoresis + Immunofixation (UPEP/UIFE)

• 24-hour urine: Quantify proteinuria (often nephrotic range in AL).
• Urine immunofixation: Detects Bence Jones protein (free light chains in urine).

Bone Marrow Biopsy

• Indication: If monoclonal protein detected or high suspicion for AL.
• Findings: Clonal plasma cells (typically 5-20%; less than 10% in most AL cases). Congo Red staining may show marrow amyloid deposits.
• Flow Cytometry: Demonstrates clonal restriction (κ or λ).

Step 2: Confirm Amyloid Deposition (Tissue Biopsy)

Goal: Demonstrate amyloid fibrils histologically.

Abdominal Fat Pad Aspirate (First-line)

• Technique: Fine-needle aspiration of subcutaneous fat (periumbilical).
• Sensitivity: 70-80% for AL; 60-65% for ATTR; 50-60% for AA.
• Advantages: Minimally invasive, safe, outpatient procedure.
• Staining: Congo Red → apple-green birefringence under polarized light.

Rectal Biopsy

• Sensitivity: 80-85% (superior to fat pad).
• Technique: Submucosal biopsy (must include submucosa and blood vessels).
• Risk: Minor bleeding.

Organ Biopsy (if fat pad/rectal negative but high suspicion)

• Renal Biopsy: Gold standard for renal amyloidosis. Shows glomerular and tubular amyloid deposits.
• Endomyocardial Biopsy: Rarely required with modern imaging (DPD/PYP scan), but definitive for cardiac AL.
• Liver Biopsy: High risk (bleeding, hepatic rupture); rarely indicated.

Step 3: Amyloid Typing (MANDATORY)

Critical: Congo Red confirms amyloid but does NOT specify type. Typing determines treatment.

Immunohistochemistry (IHC)

• Antibodies: Anti-κ, anti-λ, anti-TTR, anti-SAA.
• Limitations: Sensitivity 70-80%. Background staining can cause false positives.

Mass Spectrometry (Gold Standard)

• Technique: Laser microdissection of Congo Red-positive areas → Tandem mass spectrometry.
• Accuracy: > 95% sensitivity and specificity.
• Advantages: Identifies rare amyloid types and mixed types. [16]

Genetic Testing

• Indication: If ATTR diagnosed (distinguish wild-type from hereditary).
• Test: TTR gene sequencing (> 150 known mutations).
• Common Variants: V122I (African ancestry, 3-4% carrier frequency), T60A, V30M.

Step 4: Cardiac Imaging for ATTR

Bone Scintigraphy (DPD/PYP/HMDP Scan)

• Principle: Technetium-99m-labeled bone tracers (DPD, PYP, HMDP) avidly bind ATTR cardiac amyloid.
• Grading:
  • Grade 0: No uptake (excludes ATTR-CM).
  • Grade 1: Mild uptake (less than ribs).
  • Grade 2: Moderate (=ribs) – diagnostic for ATTR-CM.
  • Grade 3: Strong (>ribs) – diagnostic for ATTR-CM.
• Key Rule: Grade 2-3 uptake + absence of monoclonal protein = ATTR-CM (no biopsy needed). [17]
• AL Amyloidosis: Grade 0 (no uptake).

Echocardiography

• Classic Findings:
  • Increased LV wall thickness (≥12 mm) with small LV cavity.
  • Bi-atrial enlargement (severe diastolic dysfunction).
  • Granular sparkling myocardium (ground-glass appearance)—insensitive but specific.
  • Thickened interatrial septum.
  • Reduced global longitudinal strain (GLS) with apical sparing ("cherry on top" pattern).
  • Low-normal or reduced ejection fraction (despite hypertrophy).
  • Pericardial effusion (common).
• Diastolic Dysfunction: Restrictive filling pattern (E/A ratio > 2, short deceleration time).

Cardiac MRI (CMR)

• Late Gadolinium Enhancement (LGE):
  • Diffuse subendocardial or transmural LGE (circumferential pattern).
  • Inability to null myocardium (amyloid avidity for gadolinium).
• Extracellular Volume (ECV): Markedly elevated (> 40%; normal less than 28%). Correlates with amyloid burden and prognosis.
• Native T1 Mapping: Elevated (> 1100 ms; indicates expanded extracellular space). [18]

Electrocardiography (ECG)

• Voltage/Mass Mismatch: Low voltage QRS (less than 5 mm limb leads, less than 10 mm precordial) despite LV hypertrophy on echo.
• Pseudo-infarct Pattern: Poor R-wave progression, Q waves (V1-V3) mimicking old MI.
• Atrial Fibrillation: Common (30-70%).
• Conduction Disease: AV block, bundle branch block.

Differential Diagnosis: AL vs ATTR vs AA

---

5. Staging and Prognostic Assessment

AL Amyloidosis Staging Systems

Mayo Clinic Staging System (2004/2012)

Based on cardiac biomarkers:

European Modification (Includes dFLC)

Adds dFLC > 180 mg/L as third biomarker:

• Stage I: 0 biomarkers → Median survival 94 months.
• Stage II: 1 biomarker → 40 months.
• Stage III: 2 biomarkers → 14 months.
• Stage IV: 3 biomarkers → 6 months. [19]

Renal Staging

• Renal Stage 1: eGFR ≥50, proteinuria less than 5 g/24h.
• Renal Stage 2: eGFR less than 50 or proteinuria ≥5 g/24h.
• Renal Stage 3: eGFR less than 50 AND proteinuria ≥5 g/24h.

ATTR Amyloidosis Staging

NAC (National Amyloidosis Centre) Score

• Based on NT-proBNP and eGFR:
  • Stage 1: NT-proBNP less than 3000 ng/L AND eGFR ≥45 → Median survival > 60 months.
  • Stage 2: Not meeting Stage 1 or 3 → 40-50 months.
  • Stage 3: NT-proBNP ≥3000 ng/L AND eGFR less than 45 → 25 months. [20]

Gillmore Staging (2018)

• Stage I: NT-proBNP less than 3000 ng/L, eGFR ≥45.
• Stage II: Either elevated.
• Stage III: Both elevated.

---

6. Management

Management of AL Amyloidosis (Light Chain)

Principle: Rapidly suppress clonal plasma cell production to halt light chain synthesis and allow organ recovery.

First-Line Treatment: Dara-CyBorD (Daratumumab-based regimen)

ANDROMEDA Trial (2021): Landmark trial establishing Daratumumab as standard of care.

• Regimen: Daratumumab (anti-CD38 monoclonal antibody) + Cyclophosphamide + Bortezomib + Dexamethasone.
• Results: Hematologic complete response (CR) 53% vs 18% (CyBorD alone). Cardiac and renal organ responses significantly improved.
• Dosing:
  • Daratumumab 16 mg/kg IV weekly (cycles 1-2), then Q2 weeks (cycles 3-6), then Q4 weeks.
  • Cyclophosphamide 300 mg/m² PO twice weekly.
  • Bortezomib 1.3 mg/m² SC twice weekly (cycles 1-2), then weekly.
  • Dexamethasone 20-40 mg PO/IV weekly. [8]

Alternative First-Line Regimens (if Daratumumab unavailable):

• CyBorD: Cyclophosphamide + Bortezomib + Dexamethasone (prior standard).
• VCD: Bortezomib + Cyclophosphamide + Dexamethasone (similar to CyBorD).

Autologous Stem Cell Transplantation (ASCT)

• Indication: Selected patients less than 65 years, Mayo Stage I-II, ECOG 0-1, no severe cardiac involvement.
• High-dose Melphalan (140-200 mg/m²) followed by stem cell rescue.
• Outcomes: Hematologic CR 30-40%; median survival > 10 years if CR achieved.
• Mortality Risk: Treatment-related mortality 3-5% (higher in cardiac amyloidosis). [21]

Second-Line/Relapsed AL

• Daratumumab monotherapy (if not used first-line).
• Melphalan + Dexamethasone.
• Bendamustine-based regimens.
• Venetoclax (if t(11;14) translocation present—30% of AL cases).

Supportive Cardiac Care (Crucial)

• Diuretics: Loop diuretics (Furosemide 40-120 mg/day) ± Metolazone for volume overload.
• Avoid:
  • Beta-blockers: Poorly tolerated (cardiac output is heart-rate dependent; stroke volume fixed).
  • ACE inhibitors/ARBs: Risk severe hypotension (autonomic dysfunction, low preload tolerance).
  • Calcium channel blockers: Bind amyloid fibrils (increased toxicity).
  • Digoxin: Binds amyloid fibrils (increased risk of toxicity even at low levels).
• Anticoagulation: Required for atrial fibrillation (regardless of CHA₂DS₂-VASc score—atrial standstill increases stroke risk even in sinus rhythm).

Renal Supportive Care

• Diuretics: Manage nephrotic edema.
• Salt restriction: less than 2 g/day.
• Dialysis: If ESRD develops (amyloid does not clear with dialysis; consider kidney transplant post-hematologic CR).

Management of ATTR Amyloidosis (Transthyretin)

Principle: Stabilize TTR tetramers to prevent dissociation and fibril formation, or silence TTR gene to reduce production.

TTR Stabilizers

Tafamidis (Vyndaqel®)

• Mechanism: Binds to TTR tetramer and stabilizes it, preventing dissociation.
• ATTR-ACT Trial (2018): Tafamidis 80 mg vs placebo in ATTR-CM:
  • 30% reduction in all-cause mortality.
  • Reduced cardiovascular hospitalizations.
  • Slowed decline in 6-minute walk test and quality of life.
• Dosing: Tafamidis meglumine 61 mg PO daily OR Tafamidis 80 mg PO daily.
• Indication: ATTR-CM (both wild-type and variant). [7]

Diflunisal

• Mechanism: NSA ID with TTR-stabilizing properties.
• Evidence: Slows neuropathy progression in ATTRv (off-label).
• Dose: 250 mg PO twice daily.
• Caution: GI and renal toxicity (NSA ID side effects).

TTR Gene Silencers (RNA Interference)

Patisiran (Onpattro®)

• Mechanism: Small interfering RNA (siRNA) targeting TTR mRNA → reduces hepatic TTR production by 80-90%.
• APOLLO Trial: Improved neuropathy scores, quality of life, and autonomic function in ATTRv polyneuropathy.
• Dosing: 0.3 mg/kg IV every 3 weeks.
• Indication: ATTRv with polyneuropathy. [22]

Inotersen (Tegsedi®)

• Mechanism: Antisense oligonucleotide (ASO) targeting TTR mRNA.
• NEURO-TTR Trial: Improved neuropathy and quality of life in ATTRv.
• Dosing: 300 mg SC weekly.
• Adverse Effects: Thrombocytopenia (black box warning; requires platelet monitoring), glomerulonephritis.

Supportive Cardiac Care for ATTR

• Diuretics: Mainstay (loop diuretics).
• Beta-blockers: Generally avoided (similar to AL).
• Pacemaker/ICD: For symptomatic conduction disease or high-risk ventricular arrhythmia.
• Heart Transplantation: Considered for advanced ATTR-CM (liver transplant needed for ATTRv to eliminate source). Combined heart-liver transplant in selected ATTRv cases.

Management of AA Amyloidosis

Principle: Control underlying inflammatory condition to reduce SAA production.

Treat Primary Inflammatory Disease

• Rheumatoid Arthritis: Aggressive DMARD therapy (Methotrexate, anti-TNF biologics like Etanercept, Adalimumab).
• Inflammatory Bowel Disease: Anti-TNF therapy, immunomodulators.
• Familial Mediterranean Fever: Colchicine 1-2 mg/day (prevents AA amyloid formation).
• Chronic Infections: Antimicrobial therapy (e.g., tuberculosis, bronchiectasis). [23]

IL-6 Blockade

• Tocilizumab (anti-IL-6 receptor): Emerging evidence for renal AA amyloidosis regression.

Renal Supportive Care

• Dialysis: If ESRD develops.
• Kidney Transplantation: Possible if underlying inflammation controlled.

---

7. Treatment Response Monitoring

Hematologic Response (AL Amyloidosis)

• Reassess: FLC every 1-2 cycles during treatment; then every 3-6 months.

Organ Response (AL and ATTR)

Cardiac Response

• Criteria: ≥30% decrease in NT-proBNP AND decrease > 300 ng/L (if baseline NT-proBNP ≥650 ng/L).
• Time: Typically 6-12 months post-hematologic response in AL.
• Prognostic Impact: Cardiac response is strongest predictor of survival.

Renal Response

• Criteria: ≥30% decrease in proteinuria (and decrease ≥0.5 g/24h) WITHOUT ≥25% decrease in eGFR.
• Time: 6-12 months.

Hepatic Response

• Criteria: ≥50% reduction in alkaline phosphatase OR ≥2 cm reduction in liver size.

---

8. Prognosis

AL Amyloidosis

• Untreated Advanced Cardiac AL: Median survival less than 6 months.
• Mayo Stage I (with treatment): Median survival 6-10 years.
• Mayo Stage III (with treatment): Median survival 1-2 years.
• Hematologic CR with Daratumumab: Significantly improved outcomes; 5-year survival > 70% in Stage I-II.
• Cardiac Response: If achieved, median survival > 10 years. [24]

ATTR Amyloidosis

• ATTRwt (Untreated): Median survival 3-5 years from diagnosis.
• ATTRwt (Tafamidis-treated): 30% reduction in mortality; improved quality of life.
• ATTRv: Variable (depends on mutation). V122I: Median survival 2.5-3.5 years. T60A: Longer survival (5-7 years).

AA Amyloidosis

• Depends on: Control of underlying inflammation.
• Untreated: Progressive renal failure; median survival 5-10 years.
• Well-controlled inflammation: Renal function may stabilize or improve; normal lifespan possible.

---

9. Complications and Special Scenarios

Sudden Cardiac Death

• Incidence: 30-40% of deaths in AL cardiac amyloidosis.
• Mechanisms: Electromechanical dissociation, ventricular arrhythmia, complete heart block.
• Prevention: ICD consideration controversial (high defibrillation thresholds; may not prevent electromechanical dissociation).

Atrial Fibrillation and Thromboembolism

• Prevalence: 30-40% AL; 60-70% ATTR.
• Thromboembolic Risk: High even in sinus rhythm (atrial standstill, low flow, thrombus formation).
• CHA₂DS₂-VASc Underestimates Risk: Anticoagulation recommended regardless of score if cardiac amyloidosis confirmed.
• Anticoagulation: DOACs (apixaban, rivaroxaban) or warfarin (INR 2-3). [25]

End-Stage Renal Disease

• Hemodialysis: Does not clear amyloid deposits.
• Kidney Transplantation: Possible if hematologic CR achieved in AL (recurrence risk 10-20%).

Gastrointestinal Complications

• Malabsorption: Villous atrophy from amyloid infiltration.
• GI Bleeding: Mucosal fragility, vascular amyloid deposition.
• Gastroparesis/Intestinal Pseudo-obstruction: Autonomic neuropathy.

Bleeding Diathesis

• Factor X Deficiency: Amyloid fibrils bind and sequester Factor X (occurs in 10-15% of AL).
• Manifestation: Prolonged PT/aPTT, bleeding, periorbital purpura.
• Management: Factor X levels; recombinant Factor VIIa or prothrombin complex concentrate (PCC) for bleeding episodes.

Bilateral Carpal Tunnel Syndrome (ATTR Red Flag)

• Timing: Often precedes cardiac ATTR diagnosis by 5-10 years.
• Screening: Men > 50 with bilateral CTS (especially without occupational risk) should be screened for ATTR-CM (echo, DPD scan, TTR genetic testing).
• Biopsy: Carpal tunnel tissue at surgery can be sent for Congo Red staining and typing.

Orthostatic Hypotension (Autonomic Neuropathy)

• Definition: Drop > 20 mmHg systolic on standing.
• Management:
  • Increase salt and fluid intake.
  • Compression stockings.
  • Midodrine (alpha-agonist) 2.5-10 mg TID.
  • Fludrocortisone 0.1-0.2 mg daily.

---

10. Organ-Specific Manifestations: Deep Dive

Cardiac Amyloidosis: Detailed Clinical Features

Pathophysiology of Cardiac Dysfunction

• Infiltrative Restrictive Cardiomyopathy: Amyloid fibril deposition in myocardial interstitium → increased ventricular stiffness → impaired relaxation (diastolic dysfunction).
• Biventricular Involvement: Both ventricles affected (unlike hypertrophic cardiomyopathy which is often asymmetric).
• Atrial Involvement: Severe atrial infiltration → mechanical standstill → thrombosis risk even in sinus rhythm.
• Conduction System: Infiltration of AV node, His-Purkinje system → heart block, bundle branch blocks.
• Valvular Involvement: Thickening of valve leaflets (especially mitral and aortic) → regurgitation or stenosis (mild-moderate).

Progressive Stages of Cardiac Amyloidosis

Early Stage (Pre-clinical)

• Symptoms: Often asymptomatic or subtle exertional fatigue.
• Biomarkers: NT-proBNP may be minimally elevated (less than 1000 ng/L).
• Echo: Mild LV wall thickening (12-13 mm), normal EF (> 50%), abnormal GLS (less than 16%).
• ECG: Low-normal voltage, early conduction delays (PR prolongation).

Intermediate Stage (Symptomatic)

• Symptoms: NYHA Class II-III dyspnea, peripheral edema, presyncope.
• Biomarkers: NT-proBNP 1000-5000 ng/L, Troponin mildly elevated.
• Echo: Moderate LV hypertrophy (14-16 mm), EF 40-50%, bi-atrial enlargement, restrictive filling.
• ECG: Low voltage, pseudo-infarct pattern, atrial fibrillation.

Advanced Stage (End-stage)

• Symptoms: NYHA Class IV, refractory edema, syncope, cachexia.
• Biomarkers: NT-proBNP > 5000-10,000 ng/L, Troponin significantly elevated.
• Echo: Severe LV hypertrophy (> 16 mm), EF less than 40%, large pericardial effusion, severe diastolic dysfunction.
• ECG: Very low voltage, AV block, ventricular arrhythmias.
• Prognosis: Median survival 3-6 months without treatment (AL).

Echocardiographic Features: Comprehensive Analysis

Standard 2D/M-Mode Findings

• LV Wall Thickness: Typically 13-18 mm (range 12-25 mm in severe cases). Concentric pattern (unlike focal hypertrophy in HCM).
• LV Cavity Size: Small to normal (end-diastolic dimension 40-50 mm).
• Interventricular Septum: Symmetric thickening.
• Atria: Severe bi-atrial enlargement (LA volume index > 40 mL/m²).
• Interatrial Septum: Thickening (> 6 mm) is highly specific.
• Valves: Thickened leaflets (mitral, aortic); mild-moderate regurgitation common.
• Pericardium: Small-moderate pericardial effusion (30-40% of cases).

Doppler Findings

• Mitral Inflow Pattern: Restrictive physiology—E/A ratio > 2, short deceleration time (less than 150 ms).
• Tissue Doppler (e' velocity): Markedly reduced (less than 5 cm/s at septal annulus).
• E/e' Ratio: Elevated (> 15-20), indicating increased filling pressures.

Advanced Echocardiography: Strain Imaging

• Global Longitudinal Strain (GLS): Reduced (less than 16%; normal is -18 to -22%).
• Apical Sparing Pattern: Pathognomonic finding. Apex has relatively preserved strain compared to base and mid-ventricle ("cherry on top" appearance). Sensitivity 80-90% for cardiac amyloidosis.
• Strain Bull's-Eye Plot: Base/mid segments affected (red), apical segments relatively spared (yellow/green).

Renal Amyloidosis: Detailed Clinical Features

Pathophysiology of Renal Dysfunction

• Glomerular Deposition: Amyloid fibrils deposit in glomerular mesangium and capillary walls → disruption of filtration barrier → massive proteinuria.
• Tubular Involvement: Tubular basement membrane and interstitial deposition → tubular dysfunction, reduced GFR.
• Vascular Involvement: Renal arteries/arterioles → ischemia, hypertension (rare in amyloidosis).

Clinical Presentation

• Nephrotic Syndrome (Classic Triad):
  1. Heavy proteinuria (> 3.5 g/24h; often > 10 g/24h in AL).
  2. Hypoalbuminemia (less than 25 g/L).
  3. Peripheral edema (legs, sacral, facial).
• Additional Features:
  • Hyperlipidemia (compensatory hepatic synthesis).
  • Thrombophilia (loss of antithrombin III in urine → increased VTE risk).
  • Anasarca (severe generalized edema).

Laboratory Findings

• Urinalysis: 3-4+ protein, fatty casts, oval fat bodies. RBCs/WBCs typically absent (non-inflammatory).
• 24-Hour Urine Protein: 5-20 g/24h (median 10 g in AL).
• Serum Albumin: 15-25 g/L.
• Serum Creatinine: Often normal initially; progressive rise indicates advanced disease.
• eGFR: Preserved early (> 60 mL/min), declines in advanced stage.

Renal Biopsy Findings

• Light Microscopy: Acellular eosinophilic material in glomeruli, vessels, interstitium. Congo Red positive.
• Immunofluorescence: Negative or weak staining (non-immune-mediated; unlike immune-complex GN).
• Electron Microscopy: Non-branching fibrils 8-10 nm diameter, randomly oriented.

Differential Diagnosis of Nephrotic Syndrome in Amyloidosis

Neurological Amyloidosis: Detailed Clinical Features

Peripheral Neuropathy Patterns

Small Fiber Neuropathy (Early)

• Symptoms: Painful burning, tingling in feet (length-dependent).
• Signs: Reduced pin-prick and temperature sensation; preserved vibration and proprioception.
• Nerve Conduction Studies: Normal motor and sensory conduction (small fibers not assessed by standard NCS).
• Diagnosis: Skin biopsy showing reduced intraepidermal nerve fiber density; quantitative sensory testing.

Large Fiber Neuropathy (Later)

• Symptoms: Numbness, unsteady gait, weakness.
• Signs: Reduced vibration/proprioception, distal weakness, hyporeflexia.
• NCS: Reduced sensory amplitudes, prolonged latencies, slow conduction velocities.

Autonomic Neuropathy (Common in ATTRv, AL)

• Cardiovascular: Orthostatic hypotension (> 20 mmHg drop), resting tachycardia, reduced heart rate variability.
• Gastrointestinal: Early satiety (gastroparesis), diarrhea/constipation (bowel dysmotility), fecal incontinence.
• Genitourinary: Erectile dysfunction, bladder dysfunction (incomplete emptying, incontinence).
• Sudomotor: Anhidrosis (reduced sweating), heat intolerance.

Carpal Tunnel Syndrome: The ATTR Red Flag

• Epidemiology: 40-50% of ATTRwt patients have history of CTS; often bilateral and occurs 5-10 years before cardiac symptoms.
• Mechanism: Amyloid deposition in flexor retinaculum and synovium.
• Clinical Clue: Bilateral CTS in men > 50 without occupational risk factors → screen for ATTR-CM (echo, DPD scan).
• Biopsy Opportunity: Carpal tunnel release tissue should be sent for Congo Red staining and amyloid typing.

Hepatosplenic Amyloidosis

Hepatic Involvement

• Clinical: Hepatomegaly (smooth, firm, non-tender). Rarely causes significant liver dysfunction (synthetic function preserved).
• Laboratory: Elevated alkaline phosphatase (cholestatic pattern; 2-3x ULN). Transaminases usually normal. Bilirubin rarely elevated.
• Imaging: CT/MRI shows hepatomegaly without focal lesions. Liver stiffness elevated on elastography.
• Amyloid Type: AA > AL. Rare in ATTR.

Splenic Involvement

• Clinical: Splenomegaly (palpable 2-5 cm below costal margin). Usually asymptomatic.
• Imaging: Splenomegaly on ultrasound/CT.
• Complications: Rare splenic rupture (spontaneous or trauma). Hyposplenism not typical.

Gastrointestinal Amyloidosis

Clinical Manifestations

• Esophagus: Dysphagia (motility disorder), gastroesophageal reflux.
• Stomach: Early satiety, nausea, vomiting (delayed gastric emptying). Gastroparesis common in autonomic neuropathy.
• Small Intestine: Malabsorption (steatorrhea, weight loss, vitamin deficiencies). Chronic diarrhea (secretory or osmotic).
• Colon: Constipation (pseudo-obstruction), diarrhea, fecal incontinence.

Endoscopic Findings

• Macroscopic: Mucosal friability, granular appearance, polypoid lesions (rare).
• Biopsy: Submucosal biopsy (standard superficial biopsies may miss amyloid). Congo Red staining diagnostic.

Complications

• GI Bleeding: Mucosal fragility, vascular amyloid deposits. Can be severe and recurrent.
• Perforation: Rare but catastrophic complication.
• Protein-Losing Enteropathy: Intestinal protein leak → hypoalbuminemia.

Soft Tissue and Musculoskeletal Amyloidosis

Macroglossia

• Prevalence: 10-15% of AL (pathognomonic but insensitive).
• Clinical: Enlarged tongue with lateral scalloping (dental indentations). Speech difficulty, dysphagia, drooling.
• Diagnosis: Tongue biopsy (rarely needed; clinical diagnosis sufficient if other amyloid features present).

Amyloid Arthropathy

• Presentation: Symmetric polyarthritis mimicking rheumatoid arthritis. Shoulders ("shoulder pad sign"), wrists, knees.
• Shoulder Pad Sign: Bilateral shoulder soft tissue swelling (amyloid deposition in periarticular tissues).
• Imaging: Soft tissue swelling, joint effusions. Erosions absent (unlike RA).
• Synovial Fluid: Non-inflammatory (less than 2000 WBC/mm³). Congo Red staining of synovial tissue diagnostic.

Amyloid Myopathy

• Clinical: Proximal muscle weakness (difficulty rising from chair, climbing stairs). Pseudo-hypertrophy (muscles firm, enlarged).
• CK: Normal or minimally elevated (unlike inflammatory myopathy).
• EMG: Myopathic pattern (short-duration, low-amplitude motor units).
• Muscle Biopsy: Amyloid deposits in muscle interstitium. Congo Red positive.

---

11. Investigation Interpretation: Case-Based Approach

Case 1: Suspected AL Amyloidosis

Clinical Vignette: 68-year-old woman with 3-month history of progressive dyspnea, peripheral edema, and 10 kg weight loss. Frothy urine noted. No significant past medical history.

Initial Investigations

Bloods:

• FBC: Hb 105 g/L (normocytic anemia).
• U&E: Creatinine 110 μmol/L, Albumin 22 g/L.
• Serum Free Light Chains: κ 35 mg/L (normal 3.3-19.4), λ 850 mg/L (normal 5.7-26.3), κ/λ ratio 0.04 (abnormal; normal 0.26-1.65).
  • Interpretation: Marked λ clonal elevation. Abnormal ratio strongly suggests clonal plasma cell disorder (AL amyloidosis or myeloma).
• SPEP: Faint M-spike in gamma region (0.4 g/dL).
• Immunofixation: Monoclonal IgG-λ.

Urine:

• 24-Hour Urine Protein: 12 g/24h (nephrotic range).
• Urine Immunofixation: Bence Jones protein (λ light chains).

Cardiac Biomarkers:

• NT-proBNP: 6500 ng/L (markedly elevated; normal less than 125 ng/L).
• Troponin T: 0.08 μg/L (elevated; normal less than 0.014 μg/L).
  • Interpretation: Mayo Stage III (both NT-proBNP and Troponin elevated). High-risk AL amyloidosis with cardiac involvement.

ECG: Low voltage QRS (less than 5 mm limb leads), pseudo-infarct pattern (Q waves V1-V3), atrial fibrillation (110 bpm).

Echocardiography:

• LV wall thickness 16 mm (increased).
• LV EF 45% (reduced).
• Bi-atrial enlargement (LA volume index 48 mL/m²).
• Granular sparkling myocardium.
• Global longitudinal strain -10% (severely reduced; apical sparing pattern).
• Moderate pericardial effusion.
  • Interpretation: Findings highly suggestive of cardiac amyloidosis.

Abdominal Fat Pad Biopsy: Congo Red positive with apple-green birefringence under polarized light. Immunohistochemistry: Positive for λ light chains.

• Diagnosis Confirmed: AL Amyloidosis (λ type) with cardiac and renal involvement.

Bone Marrow Biopsy: 8% clonal plasma cells (κ/λ ratio 0.05 on flow cytometry, confirming λ clonality).

Staging: Mayo Stage III (high-risk), Renal Stage 3.

Management Plan:

• Urgent hematology referral.
• Initiate Dara-CyBorD chemotherapy within 5 days.
• Diuretics (Furosemide 80 mg BD) for volume overload.
• Anticoagulation (Apixaban 5 mg BD) for atrial fibrillation.
• Avoid beta-blockers, ACE inhibitors.

---

Case 2: Suspected ATTR Amyloidosis

Clinical Vignette: 78-year-old man with 18-month history of progressive breathlessness and bilateral ankle swelling. Past history of bilateral carpal tunnel syndrome (operated 6 years ago). No family history of heart disease.

Initial Investigations

Bloods:

• Serum Free Light Chains: κ 18 mg/L, λ 20 mg/L, κ/λ ratio 0.90 (normal).
• SPEP: No monoclonal band.
• Immunofixation: Negative.
  • Interpretation: No evidence of monoclonal protein. AL amyloidosis unlikely; ATTR or AA more likely.

Cardiac Biomarkers:

• NT-proBNP: 2500 ng/L (elevated).
• Troponin T: 0.025 μg/L (mildly elevated).

ECG: Low voltage QRS, PR interval 220 ms (first-degree AV block), sinus rhythm.

Echocardiography:

• LV wall thickness 15 mm (increased).
• LV EF 50% (preserved).
• Bi-atrial enlargement.
• Global longitudinal strain -12% with apical sparing.
• Restrictive mitral inflow pattern (E/A ratio 2.5).

DPD Bone Scintigraphy:

• Grade 3 cardiac uptake (myocardial uptake greater than ribs).
  • Interpretation: Diagnostic for ATTR cardiac amyloidosis (no biopsy needed given absence of monoclonal protein).

TTR Genetic Testing: No pathogenic mutation detected.

• Final Diagnosis: Wild-type ATTR (ATTRwt) Cardiac Amyloidosis.

Staging: NAC Stage 2 (NT-proBNP > 3000 but eGFR > 45).

Management Plan:

• Tafamidis 80 mg PO daily.
• Diuretics (Furosemide 40 mg daily).
• Cardiology follow-up for consideration of pacemaker (first-degree AV block may progress).

---

Case 3: Suspected AA Amyloidosis

Clinical Vignette: 52-year-old woman with 20-year history of rheumatoid arthritis (RA), poorly controlled despite DMARDs. Presents with progressive ankle swelling and fatigue. Urine dipstick shows 3+ protein.

Initial Investigations

Bloods:

• Inflammatory Markers: CRP 85 mg/L (markedly elevated), ESR 95 mm/h.
• Serum Free Light Chains: Normal ratio (0.85).
• SPEP/Immunofixation: Negative.
• Albumin: 25 g/L (low).

Urine:

• 24-Hour Urine Protein: 8 g/24h (nephrotic range).

Renal Biopsy: Congo Red positive. Mass spectrometry confirms AA amyloid (serum amyloid A protein).

• Diagnosis Confirmed: AA Amyloidosis secondary to rheumatoid arthritis.

Management Plan:

• Aggressive RA control: Initiate anti-TNF therapy (Adalimumab or Etanercept).
• Consider Tocilizumab (IL-6 inhibitor) for dual benefit (RA control + potential AA amyloid regression).
• Diuretics for edema.
• Nephrology follow-up (risk of progression to ESRD).

---

12. Differential Diagnoses: Comprehensive Tables

Causes of Left Ventricular Hypertrophy

Causes of Nephrotic Syndrome in Adults

Causes of Peripheral Neuropathy with Autonomic Dysfunction

---

13. Treatment Protocols: Detailed Regimens

AL Amyloidosis: First-Line Chemotherapy Protocols

Dara-CyBorD (Standard of Care)

Daratumumab:

• Loading Phase: 16 mg/kg IV weekly for Cycles 1-2 (8 doses).
• Consolidation Phase: 16 mg/kg IV every 2 weeks for Cycles 3-6 (12 doses).
• Maintenance Phase: 16 mg/kg IV every 4 weeks from Cycle 7 onwards.
• Premedication: Paracetamol 1 g, antihistamine (cetirizine 10 mg), corticosteroid (dexamethasone 20 mg IV).
• Infusion-Related Reactions: Common (40-50% first infusion). Slow infusion rate if occurs.

Cyclophosphamide:

• Dose: 300 mg/m² PO on Days 1, 8, 15, 22 of each 28-day cycle.
• Duration: 6 cycles.
• Monitoring: FBC (risk of cytopenias), urine (hemorrhagic cystitis rare at this dose).

Bortezomib:

• Dose: 1.3 mg/m² SC on Days 1, 8, 15, 22 (Cycles 1-2); then Days 1, 15 (Cycles 3-6).
• Duration: 6 cycles.
• Side Effects: Peripheral neuropathy (dose-reduce if Grade 2-3), herpes zoster reactivation (give acyclovir prophylaxis 400 mg BD).

Dexamethasone:

• Dose: 20-40 mg PO/IV on Days 1, 8, 15, 22 of each cycle.
• Caution: Reduce to 20 mg if > 70 years or frail. Risk of fluid retention (exacerbates cardiac failure).

Cycle Length: 28 days. Total Duration: 6 cycles (24 weeks).

Response Assessment:

• FLC every 2 cycles.
• NT-proBNP every 2 cycles.
• Bone marrow reassessment at end of treatment (confirm hematologic CR).

---

CyBorD (Alternative if Daratumumab Unavailable)

Cyclophosphamide: 300 mg/m² PO Days 1, 8, 15. Bortezomib: 1.3 mg/m² SC Days 1, 8, 15, 22. Dexamethasone: 40 mg PO Days 1, 8, 15, 22.

Cycle Length: 28 days. Duration: 6-9 cycles.

Expected Outcomes:

• Hematologic CR: 20-30%.
• VGPR: 40-50%.
• Organ response: 20-30% (cardiac), 30-40% (renal).

---

ATTR Amyloidosis: Disease-Modifying Therapies

Tafamidis Dosing and Monitoring

Tafamidis Meglumine (Vyndamax®):

• Dose: 61 mg PO once daily.
• Alternative: Tafamidis 80 mg (free acid formulation, Vyndaqel®) PO once daily.
• Timing: Take with or without food, same time each day.
• Monitoring:
  • Baseline: NT-proBNP, Troponin, ECG, Echo, 6-minute walk test (6MWT).
  • Follow-up: NT-proBNP every 3-6 months, Echo every 6-12 months, 6MWT every 6 months.
• Expected Outcomes: Slows decline in 6MWT, reduces hospitalization, 30% mortality reduction over 30 months.

Patisiran (ATTRv Polyneuropathy)

Dose: 0.3 mg/kg IV every 3 weeks. Infusion: Over 80 minutes. Premedication (given 60 minutes before infusion):

• Dexamethasone 10 mg IV.
• Paracetamol 500 mg PO.
• Antihistamine (cetirizine 10 mg PO).
• Ranitidine 50 mg IV.

Monitoring:

• Baseline: Neuropathy Impairment Score (NIS), Norfolk QOL, vitamin A levels.
• Follow-up: NIS and QOL every 9 months, vitamin A supplementation (2500-3000 IU daily; Patisiran reduces retinol-binding protein).

Expected Outcomes: Improvement in neuropathy scores, halt or reverse progression.

---

14. Key Clinical Pearls

Exam-Focused Points

1. AL is a Hematologic Emergency: Rapid chemotherapy within days of diagnosis is critical. Median survival less than 6 months untreated in Mayo Stage III.
2. Macroglossia: Pathognomonic for AL (but only 15% sensitive). If present, AL is virtually certain.
3. "Granular Sparkling" Myocardium: Classic echo description (low sensitivity but high specificity).
4. Low Voltage ECG + LV Hypertrophy (Voltage/Mass Mismatch): Classic for cardiac amyloid. LV is thick with amyloid protein (not muscle), so QRS voltage is paradoxically low.
5. Periorbital Purpura ("Raccoon Eyes"): Induced by Valsalva, coughing, or endoscopy. Pathognomonic for AL.
6. Avoid Beta-Blockers in Cardiac Amyloid: Stroke volume is fixed (restrictive physiology); cardiac output depends on heart rate. Beta-blockade can cause hemodynamic collapse.
7. DPD/PYP Scan Grade 2-3 + No Monoclonal Protein = ATTR-CM: No biopsy needed (non-invasive diagnosis).
8. Bilateral Carpal Tunnel Syndrome in Men > 50: Red flag for ATTR—evaluate for cardiac involvement.
9. Digoxin Toxicity: Amyloid fibrils bind digoxin → toxicity even at therapeutic levels. Avoid in amyloidosis.
10. Anticoagulation in AF with Amyloid: Required regardless of CHA₂DS₂-VASc (atrial standstill increases stroke risk).

Common Exam Scenarios

Scenario 1: Elderly man with heart failure, preserved EF, bilateral carpal tunnel syndrome, and LV hypertrophy on echo.

• Diagnosis: ATTRwt (wild-type ATTR cardiac amyloidosis).
• Next Step: DPD/PYP bone scan (will show Grade 2-3 uptake); check serum FLC to exclude AL.

Scenario 2: Patient with nephrotic syndrome, macroglossia, periorbital purpura, and easy bruising.

• Diagnosis: AL amyloidosis.
• Next Step: Serum FLC, SPEP/SIFE, fat pad biopsy (Congo Red), bone marrow biopsy.

Scenario 3: Patient with longstanding rheumatoid arthritis presents with proteinuria and hepatosplenomegaly.

• Diagnosis: AA amyloidosis secondary to RA.
• Next Step: Renal biopsy (Congo Red positive; immunohistochemistry/mass spec confirms SAA).

Scenario 4: Patient with heart failure, low-voltage ECG but LV wall thickness 16 mm on echo, and "granular sparkling" appearance.

• Diagnosis: Cardiac amyloidosis (AL vs ATTR).
• Next Step: Serum FLC to screen for AL; if negative, DPD scan for ATTR.

Practical Exam Tips and High-Yield Facts

1. Think Amyloid in Any "Unexplained" Multi-System Disease: Combination of heart failure + proteinuria, or neuropathy + cardiomyopathy should trigger amyloid workup.
2. AL vs ATTR Distinction is Treatment-Critical: AL requires urgent chemotherapy (days); ATTR is managed with stabilizers/silencers (non-urgent).
3. DPD Scan Revolutionized ATTR Diagnosis: Grade 2-3 uptake + absent monoclonal protein = ATTR-CM (biopsy not needed). This is a recent paradigm shift.
4. Apical Sparing on Strain Echo: "Cherry on top" pattern is 80-90% sensitive for cardiac amyloidosis. Learn to recognize bull's-eye plots.
5. Macroglossia is Pathognomonic but Rare: Only 15% of AL cases, but if present, diagnosis is virtually certain.
6. Bilateral CTS Precedes Cardiac ATTR by Years: Men > 50 with bilateral CTS should be screened for subclinical ATTR-CM.
7. Mayo Staging Predicts AL Prognosis: Stage I (low NT-proBNP and Troponin) has > 5-year survival; Stage IV (less than 6 months). Critical for urgent vs. palliative decisions.
8. Never Use Digoxin in Amyloidosis: Amyloid fibrils bind digoxin → unpredictable toxicity even at low doses. Same applies to calcium channel blockers.
9. Anticoagulation for AF is Mandatory: Even CHA₂DS₂-VASc score 0 patients with cardiac amyloidosis need anticoagulation (atrial mechanical dysfunction causes thrombus formation).
10. Factor X Deficiency in AL: Amyloid fibrils adsorb Factor X. Check Factor X levels if unexplained bleeding or prolonged PT/aPTT.
11. Lambda > Kappa in AL: 75% of AL amyloidosis involves λ light chains (opposite to normal serum ratio and myeloma).
12. SAA Levels Track AA Amyloidosis Activity: Serum amyloid A protein levels should be less than 10 mg/L to prevent AA deposition. Monitor inflammatory control.
13. Tafamidis is Expensive but Transformative: Cost ~$225,000/year, but ATTR-ACT showed clear mortality benefit. Cost-effectiveness debated.
14. Daratumumab Transformed AL Outcomes: ANDROMEDA trial (2021) established > 50% CR rate (vs 18% without). New standard of care.
15. Amyloid "Masquerades": Can mimic myeloma (AL), HFpEF (ATTR), chronic kidney disease (AA), or inflammatory arthritis (AA). Always consider in differential.

---

15. Advanced Topics

Emerging Therapies and Clinical Trials

AL Amyloidosis: Novel Agents

Venetoclax (BCL-2 Inhibitor):

• Indication: AL amyloidosis with t(11;14) translocation (30% of AL cases).
• Mechanism: Induces apoptosis in plasma cells with t(11;14).
• Clinical Trial Data: Phase 2 studies show 40-50% hematologic response rate in relapsed/refractory AL.
• Dosing: 400-800 mg PO daily (ramp-up schedule to prevent tumor lysis syndrome).

Isatuximab (Anti-CD38 Monoclonal Antibody):

• Similar to Daratumumab: Alternative anti-CD38 agent under investigation for AL.

CAEL-101 (Anti-Amyloid Fibril Antibody):

• Mechanism: Monoclonal antibody targeting misfolded light chain fibrils → enhances clearance.
• Phase 2 Trial: Shows cardiac and renal organ responses even without hematologic response.
• Future Promise: Could be combined with chemotherapy for synergistic effect.

ATTR Amyloidosis: Gene Editing and Novel Stabilizers

Vutrisiran (Next-Generation siRNA):

• Mechanism: siRNA targeting TTR mRNA (similar to Patisiran but improved pharmacokinetics).
• HELIOS-A Trial: Non-inferiority to Patisiran for ATTRv polyneuropathy. Subcutaneous administration every 3 months (vs IV every 3 weeks for Patisiran).

Acoramidis (AG10):

• Mechanism: High-potency TTR stabilizer (> 100x more potent than Tafamidis in vitro).
• ATTRibute-CM Trial (2024): Phase 3 results pending. May offer superior efficacy.

CRISPR-Cas9 Gene Editing (NTLA-2001):

• Mechanism: In vivo gene editing to permanently knock down TTR gene in hepatocytes.
• Phase 1 Trial: Single IV dose → sustained 90% reduction in serum TTR for > 12 months.
• Revolutionary Potential: One-time treatment could cure ATTRv (and possibly benefit ATTRwt).

AA Amyloidosis: Targeted Anti-Cytokine Therapy

Canakinumab (Anti-IL-1β):

• Indication: Familial Mediterranean fever with AA amyloidosis.
• Evidence: Case series show renal function stabilization.

Tocilizumab (Anti-IL-6 Receptor):

• Mechanism: Blocks IL-6 → reduces SAA production.
• Evidence: Case series in AA amyloidosis secondary to RA/IBD show proteinuria reduction and renal stabilization.

---

Transplantation in Amyloidosis

Autologous Stem Cell Transplantation (AL Amyloidosis)

Patient Selection Criteria:

• Age less than 65 years (some centers extend to 70).
• ECOG performance status 0-1.
• Mayo Stage I or II (Stage III/IV have high treatment-related mortality).
• No severe cardiac involvement (NT-proBNP less than 5000 ng/L, Troponin less than 0.06 μg/L).
• Adequate organ function (eGFR > 30, LVEF > 40%).

Conditioning Regimen:

• High-dose Melphalan 140-200 mg/m² (dose-adjusted based on age, renal function, cardiac involvement).
• Stem cell infusion Day 0 (after 24-48h from Melphalan).

Outcomes:

• Treatment-Related Mortality: 3-5% (historically 10-15%; improved with better patient selection).
• Hematologic CR: 30-40%.
• Median Survival if CR: > 10 years.

Post-Transplant Monitoring:

• FLC every 1-3 months (monitor for relapse).
• NT-proBNP (cardiac response).
• Bone marrow biopsy at 1 year (confirm CR).

Organ Transplantation

Heart Transplantation (AL Amyloidosis):

• Indication: End-stage cardiac AL after achieving hematologic CR (to prevent amyloid recurrence in graft).
• Outcomes: 5-year survival 50-60% (acceptable in carefully selected patients).
• Challenge: Recurrence of amyloid in graft if hematologic relapse occurs.

Heart Transplantation (ATTR Amyloidosis):

• ATTRwt: Heart transplant alone (liver produces TTR but no mutation; ongoing debate about necessity of liver transplant).
• ATTRv: Combined heart-liver transplantation (liver is source of mutant TTR; must be replaced to prevent recurrence).
• Outcomes: 5-year survival 60-70% for combined transplant.

Kidney Transplantation:

• AL Amyloidosis: Feasible if hematologic CR maintained for > 1 year. Recurrence risk 10-20%.
• AA Amyloidosis: Feasible if underlying inflammation controlled (SAA less than 10 mg/L). 5-year graft survival ~60%.

Liver Transplantation (ATTRv):

• Indication: Dominant hepatic or polyneuropathy phenotype in young patients with ATTRv.
• Rationale: Replaces source of mutant TTR.
• Outcomes: Halts neuropathy progression in 50-70%; cardiac deposition may continue (wild-type TTR from donor liver can still deposit in some mutations).

---

Biomarkers and Risk Stratification: Cutting-Edge

Novel Cardiac Biomarkers

Soluble ST2 (sST2):

• Role: Marker of cardiac fibrosis and remodeling.
• Prognostic Value: Elevated sST2 independently predicts mortality in both AL and ATTR cardiac amyloidosis.
• Cutoff: > 35 ng/mL associated with poor prognosis.

Growth Differentiation Factor-15 (GDF-15):

• Role: Stress-response cytokine.
• Evidence: Elevated in cardiac amyloidosis; correlates with disease severity.

MicroRNAs (miRNA)**:

• Circulating miRNAs: Differentially expressed in AL vs ATTR vs controls.
• Future Potential: Non-invasive diagnostic and prognostic tool under investigation.

Imaging Biomarkers

Extracellular Volume (ECV) on Cardiac MRI:

• Measurement: Quantifies amyloid burden (ECV = % of myocardium occupied by extracellular space).
• Normal: less than 28%.
• Amyloidosis: > 40-50% (severe cases > 60%).
• Prognostic: ECV > 45% predicts mortality independently of NT-proBNP and Troponin.

Serum Amyloid P (SAP) Scintigraphy:

• Principle: Radiolabeled SAP (123I-SAP) binds all amyloid deposits (not specific to organ).
• Use: Quantifies whole-body amyloid burden in AA amyloidosis (UK National Amyloidosis Centre).
• Limitation: Not widely available; limited use in AL and ATTR.

---

Special Populations

Amyloidosis in Pregnancy

Challenges:

• Rare: Most patients are post-menopausal (AL/ATTR). ATTRv may occur in reproductive age.
• Cardiac Amyloidosis: Restrictive cardiomyopathy poorly tolerates pregnancy hemodynamics (increased preload, cardiac output demands).
• Management:
  • Multidisciplinary care (cardiology, hematology, obstetrics).
  • Diuretics (safe in pregnancy).
  • Avoid tafamidis (insufficient safety data; teratogenicity unknown).
  • Chemotherapy (if AL): Bortezomib considered safest in pregnancy; Daratumumab insufficient data.

Delivery:

• Planned delivery at tertiary center.
• Cesarean section often preferred (avoid hemodynamic stress of labor).

Dialysis-Related Amyloidosis (β2-Microglobulin Amyloidosis)

Mechanism:

• Long-term hemodialysis → accumulation of β2-microglobulin (normally cleared by kidneys) → amyloid fibril formation.
• Affected Organs: Bones, joints, soft tissues (carpal tunnel syndrome, destructive spondyloarthropathy).

Clinical Features:

• Carpal tunnel syndrome (bilateral).
• Bone cysts and pathological fractures.
• Shoulder arthropathy ("shoulder pad sign").

Diagnosis:

• Congo Red positive tissue (synovium, bone).
• Immunohistochemistry: Positive for β2-microglobulin.

Prevention/Treatment:

• High-flux dialysis membranes (clear β2-microglobulin more effectively).
• Renal transplantation (curative; stops β2-microglobulin accumulation).

---

16. Complications: Detailed Management

Cardiac Complications

Ventricular Arrhythmias and Sudden Cardiac Death

Incidence: 25-40% of cardiac amyloidosis deaths are sudden (ventricular fibrillation, electromechanical dissociation).

Risk Stratification:

• High Risk: Mayo Stage III/IV (AL), syncope, non-sustained VT on monitoring, severely reduced EF (less than 30%).

ICD Consideration:

• Controversial: Traditional ICD efficacy unclear in amyloidosis (high defibrillation thresholds due to infiltration; electromechanical dissociation not shockable).
• Evidence: Observational data suggest ICD benefit in younger patients with ATTR and ventricular arrhythmias.
• Guidelines: Consider in patients with sustained VT, cardiac arrest survivors, or high-risk features if life expectancy > 1 year.

Complete Heart Block

Incidence: 5-10% require permanent pacemaker.

Indications for Pacing:

• Symptomatic bradycardia.
• Second-degree AV block (Mobitz II) or third-degree AV block.
• First-degree AV block with symptoms (progressive conduction disease likely).

Device Choice:

• Dual-chamber pacemaker (DDD) for isolated conduction disease.
• CRT-D (cardiac resynchronization therapy defibrillator) rarely beneficial in amyloidosis (restrictive physiology limits CRT response).

Renal Complications

Progression to End-Stage Renal Disease

Incidence:

• AL Amyloidosis: 20-30% require dialysis within 2 years if no organ response to treatment.
• AA Amyloidosis: 50% progress to ESRD within 5-10 years if inflammation not controlled.

Hemodialysis in Amyloidosis:

• Challenge: Amyloid deposits do not clear with dialysis (unlike uremic toxins).
• Hemodynamic Intolerance: Cardiac amyloidosis patients poorly tolerate fluid shifts.
• Modality: Slow, gentle ultrafiltration. Consider peritoneal dialysis if hemodynamically unstable.

Renal Transplantation:

• AL: Possible if hematologic CR for > 1 year. Immunosuppression may increase myeloma/plasma cell disorder risk.
• AA: Possible if SAA less than 10 mg/L sustained. Recurrence risk 10-20% if inflammation recurs.

Gastrointestinal Complications

Gastrointestinal Bleeding

Mechanism: Mucosal vascular amyloid deposits → fragility, spontaneous or post-endoscopy bleeding.

Management:

• Acute: Volume resuscitation, blood transfusion, endoscopy (may require argon plasma coagulation, hemostatic clips).
• Recurrent: Consider tranexamic acid (antifibrinolytic). Rarely, surgical resection if focal bleeding source identified.

Pseudo-Obstruction

Clinical: Abdominal distension, vomiting, absent bowel sounds (mimics mechanical obstruction but no structural blockage).

Mechanism: Autonomic neuropathy → loss of intestinal motility.

Management:

• Nasogastric decompression.
• Prokinetics (metoclopramide, erythromycin) often ineffective.
• Total parenteral nutrition (TPN) if prolonged.

Hemorrhagic Complications

Factor X Deficiency

Incidence: 10-15% of AL amyloidosis.

Mechanism: Amyloid fibrils adsorb Factor X from circulation.

Diagnosis:

• Prolonged PT and aPTT (both intrinsic and extrinsic pathways affected).
• Factor X Activity: less than 50% (normal 70-120%).

Management:

• Minor Bleeding: Observation, local measures.
• Major Bleeding: Recombinant Factor VIIa (90 μg/kg IV bolus) or prothrombin complex concentrate (PCC).
• Surgery/Procedures: Prophylactic Factor VIIa or PCC before invasive procedures.

Note: Fresh frozen plasma (FFP) infusion ineffective (Factor X is immediately adsorbed by amyloid).

---

17. Prognosis and Quality of Life

Survival by Type and Stage (Contemporary Data with Modern Therapies)

AL Amyloidosis (with Daratumumab-Based Therapy)

Key Survival Predictors:

1. Hematologic Response: CR vs VGPR vs PR vs No Response (most important).
2. Cardiac Response: > 30% NT-proBNP reduction (stronger than hematologic response for survival).
3. dFLC: less than 40 mg/L target.

ATTR Amyloidosis (with Tafamidis)

Key Survival Predictors:

1. NAC Staging: Stage I vs II vs III.
2. NYHA Class: Class I-II vs III-IV.
3. 6-Minute Walk Distance: > 300 m vs less than 300 m.

AA Amyloidosis

---

Quality of Life Considerations

Physical Burden:

• Fatigue: Multifactorial (anemia, cardiac dysfunction, autonomic neuropathy). Most debilitating symptom.
• Dyspnea: Limits activities of daily living.
• Neuropathic Pain: Chronic, difficult to control (gabapentin, pregabalin, duloxetine often required).

Psychological Burden:

• Anxiety/Depression: High prevalence (40-50%) due to poor prognosis, chronic symptoms.
• Cognitive Impact: Brain fog reported in cardiac amyloidosis (reduced cerebral perfusion).

Social Burden:

• Employment: Many patients unable to work due to symptoms.
• Financial Toxicity: Tafamidis costs ~$225,000/year; Daratumumab ~$150,000/year. Insurance coverage variable.

Supportive Care Interventions:

• Palliative Care: Early integration (concurrent with disease-modifying therapy) improves QOL.
• Physical Therapy: Maintains functional capacity, prevents deconditioning.
• Psychological Support: CBT, support groups (Amyloidosis Foundation).

---

18. Patient Explanation

What is Amyloidosis?

"Amyloidosis is a condition where an abnormal protein (called amyloid) builds up in your body's tissues and organs. Think of it like a starch or gum that clogs up the machinery of your organs.

• If it builds up in the heart, your heart becomes stiff and can't pump blood properly (even though the heart muscle looks thick on scans, it's weak).
• If it builds up in the kidneys, they leak protein into your urine, causing swelling.
• If it builds up in the nerves, you may feel numbness, tingling, or dizziness when standing."

What Causes It?

"There are different types, depending on which protein is involved:

1. AL Amyloidosis: Caused by abnormal cells in your bone marrow making a harmful protein (light chains). This is the most urgent type and requires chemotherapy to stop these cells.
2. ATTR Amyloidosis: Caused by a protein made by your liver (transthyretin) that becomes unstable with aging or due to a gene you inherited. New medications can stabilize this protein.
3. AA Amyloidosis: Caused by long-term inflammation (like arthritis or chronic infections). Treating the inflammation is key."

Is it Cancer?

"AL amyloidosis is related to a bone marrow problem similar to myeloma (a blood cancer), and we use chemotherapy similar to myeloma treatment. However, it doesn't form solid tumors.

The other types (ATTR and AA) are not cancer—they're related to aging, genetics, or inflammation."

What is the Treatment?

"Treatment depends entirely on the type of amyloidosis:

1. For AL Amyloidosis: We use chemotherapy (often with a drug called Daratumumab) to stop the bone marrow from making the harmful protein. The goal is to act quickly to protect your organs.
2. For ATTR Amyloidosis: We use newer medications (like Tafamidis) that stabilize the protein and prevent it from depositing. These are tablets taken daily.
3. For AA Amyloidosis: We treat the underlying inflammation (e.g., better control of your arthritis or infection) to reduce the protein production."

What is the Outlook?

"Amyloidosis used to be very difficult to treat, but new medications have dramatically improved outcomes:

• AL Amyloidosis: With modern chemotherapy, many patients achieve complete remission and live for many years.
• ATTR Amyloidosis: Tafamidis and similar drugs slow the disease progression significantly and improve quality of life.

Early diagnosis and treatment are critical—the sooner we start, the better we can protect your organs."

---

12. Evidence & Guidelines

Key Guidelines

Landmark Trials

ANDROMEDA (2021): Daratumumab in AL Amyloidosis

• Design: Phase 3 RCT; Daratumumab-CyBorD vs CyBorD in newly diagnosed AL.
• Results: Hematologic CR 53% vs 18% (pless than 0.001). Improved cardiac and renal responses.
• Impact: Established Daratumumab as standard first-line therapy. [8]

ATTR-ACT (2018): Tafamidis in ATTR Cardiomyopathy

• Design: Phase 3 RCT; Tafamidis (61 mg or 80 mg) vs placebo in ATTR-CM.
• Results: 30% reduction in all-cause mortality; reduced CV hospitalizations; slowed functional decline.
• Impact: First disease-modifying therapy for ATTR-CM; FDA/EMA approved. [7]

APOLLO (2018): Patisiran in ATTRv Polyneuropathy

• Design: Phase 3 RCT; Patisiran (siRNA) vs placebo in hereditary ATTR polyneuropathy.
• Results: Improved neuropathy scores, quality of life, and autonomic function.
• Impact: First RNA interference therapy for ATTR; established gene silencing as effective strategy. [22]

Evidence-Based Recommendations

---

13. References

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. doi:10.1056/NEJMra023144

2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641-2654. doi:10.1016/S0140-6736(15)01274-X

3. Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159-168. doi:10.1182/blood-2016-01-629790

4. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357-1377. doi:10.1161/CIRCULATIONAHA.116.024438

5. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361-2371. doi:10.1056/NEJMoa070265

6. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-2594. doi:10.1093/eurheartj/ehv338

7. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689

8. Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021;385(1):46-58. doi:10.1056/NEJMoa2028631

9. Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585-603. doi:10.1016/j.rdc.2018.06.004

10. Guan J, Mishra S, Qiu Y, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med. 2014;6(11):1493-1507. doi:10.15252/emmm.201404190

11. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-2891. doi:10.1016/j.jacc.2019.04.003

12. Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis. 1999;58(2):96-102. doi:10.1136/ard.58.2.96

13. Picken MM. The Pathology of Amyloidosis in Classification: A Review. Acta Haematol. 2020;143(4):322-334. doi:10.1159/000506696

14. Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018;72(17):2040-2050. doi:10.1016/j.jacc.2018.07.092

15. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. doi:10.1200/JCO.2004.03.029

16. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-4959. doi:10.1182/blood-2009-07-230722

17. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-2412. doi:10.1161/CIRCULATIONAHA.116.021612

18. Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157-165. doi:10.1016/j.jcmg.2013.10.008

19. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995. doi:10.1200/JCO.2011.38.5724

20. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806. doi:10.1093/eurheartj/ehx589

21. Sidiqi MH, Aljama MA, Buadi FK, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018;36(13):1323-1329. doi:10.1200/JCO.2017.76.9554

22. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21. doi:10.1056/NEJMoa1716153

23. Papalopoulos PA, Wechalekar AD. Tocilizumab, another biological agent for AA amyloidosis associated with inflammatory bowel disease. Clin Kidney J. 2016;9(3):492-494. doi:10.1093/ckj/sfw026

24. Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612-615. doi:10.1182/blood-2015-01-620302

25. Martinez-Naharro A, Patel R, Kotecha T, et al. Cardiovascular Magnetic Resonance in Light-Chain Amyloidosis to Guide Treatment. Eur Heart J. 2022;43(45):4722-4735. doi:10.1093/eurheartj/ehac363